Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
This study evaluated the microscopic changes in leiomyomata following the use of a gonadotropin releasing hormone (GnRH) agonist. Seventeen women with symptomatic leiomyomata were included. Nine were treated with a GnRH agonist for three to six months prior to surgery, and the remaining eight served as controls. Following myomectomy, paraffin sections were prepared from the tumors. These sections were examined microscopically by two gynecologic pathologists, who were blind to the patient groups. The results showed increased cellularity and hyalinization in leiomyomata following GnRH agonist treatment.
Cohen
D
D
Department of Obstetrics and Gynecology, State University of New York Health Science Center, Syracuse 13210.
Mazur
M T
MT
Jozefczyk
M A
MA
Badawy
S Z
SZ
D000328:Adult; D002452:Cell Count / Q000187:drug effects; D005260:Female; D006801:Humans; D006818:Hyalin / Q000187:drug effects*; D007889:Leiomyoma / Q000145:classification / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D016729:Leuprolide / Q000494:pharmacology / Q000627:therapeutic use*; D008940:Mitotic Index / Q000187:drug effects; D017274:Nafarelin / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016037:Single-Blind Method; D014594:Uterine Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery
D017274:Nafarelin; D016729:Leuprolide